Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy

Journal of Clinical Oncology

Volumn 31, Issue 13, 2013, Pages

  Satzger, Imke ^a   Degen, Annette ^a   Asper, Hiba ^a   Kapp, Alexander ^a   Hauschild, Axel ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; GENE MUTATION; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA CELL; METASTATIC MELANOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION DERMATITIS; SKIN TOXICITY; CHEMICALLY INDUCED DISORDER; CHEMORADIOTHERAPY; CONTACT DERMATITIS; DRUG ANTAGONISM; GENETICS; MELANOMA; MIDDLE AGED; PATHOLOGY; RADIATION INJURY; SKIN TUMOR;

AGED; CHEMORADIOTHERAPY; DERMATITIS, CONTACT; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84883065232     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.4265     Document Type: Article

References (10)

1. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
2. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
3. Testori A, Rutkowski P, Marsden J, et al: Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 20:vi22-vi29, 2009 (suppl 6)
4. Sambade MJ, Peters EC, Thomas NE, et al: Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98:394-399, 2011
5. Chung EJ, Brown AP, Asano H, et al: In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res 15:3050-3057, 2009
6. Hildesheim J, Awwad RT, Fornace AJ Jr: p38 Mitogen-activated protein kinase inhibitor protects the epidermis against the acute damaging effects of ultraviolet irradiation by blocking apoptosis and inflammatory responses. J Invest Dermatol 122:497-502, 2004
7. Li S, Zhu F, Zykova T, et al: T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway. J Biol Chem 286:29601-29609, 2011
8. Oberholzer PA, Kee D, Dziunycz P, et al: RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316-321, 2012
9. Su F, Viros A, Milagre C, et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215, 2012
10. Chu EY, Wanat KA, Miller CJ, et al: Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol 67:1265-1272, 2012